{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:18:24Z","timestamp":1787728704198,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020300","name":"National Institutes of Biomedical Innovation, Health and Nutrition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      A rare muscle disease, GNE myopathy is caused by mutations in the\n                      <jats:italic>GNE<\/jats:italic>\n                      gene involved in sialic acid biosynthesis. Our recent phase II\/III study has indicated that oral administration of aceneuramic acid to patients slows disease progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a phase III, randomized, placebo-controlled, double-blind, parallel-group, multicenter study. Participants were assigned to receive an extended-release formulation of aceneuramic acid (SA-ER) or placebo. Changes in muscle strength and function over 48\u00a0weeks were compared between treatment groups using change in the upper extremity composite (UEC) score from baseline to Week 48 as the primary endpoint and the investigator-assessed efficacy rate as the key secondary endpoint. For safety, adverse events, vital signs, body weight, electrocardiogram, and clinical laboratory results were monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 14 patients were enrolled and given SA-ER (n\u2009=\u200910) or placebo (n\u2009=\u20094) tablets orally. Decrease in least square mean (LSM) change in UEC score at Week 48 with SA-ER (\u2212\u20090.115\u00a0kg) was numerically smaller as compared with placebo (\u2212\u20092.625\u00a0kg), with LSM difference (95% confidence interval) of 2.510 (\u2212\u20091.720\u00a0to\u00a06.740)\u00a0kg. In addition, efficacy was higher with SA-ER as compared with placebo. No clinically significant adverse events or other safety concerns were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study reproducibly showed a trend towards slowing of loss of muscle strength and function with orally administered SA-ER, indicating supplementation with sialic acid might be a promising replacement therapy for GNE myopathy.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration number<\/jats:italic>\n                      : ClinicalTrials.gov (NCT04671472).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02850-y","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T03:02:25Z","timestamp":1691722945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy confirmation study of aceneuramic acid administration for GNE myopathy in Japan"],"prefix":"10.1186","volume":"18","author":[{"given":"Madoka","family":"Mori-Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8880-8554","authenticated-orcid":false,"given":"Naoki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori P.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hashizume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Nakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Warita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Tateyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichizo","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"issue":"1","key":"2850_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0022-510X(81)90067-8","volume":"51","author":"I Nonaka","year":"1981","unstructured":"Nonaka I, Sunohara N, Ishiura S, Satoyoshi E. Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation. J Neurol Sci. 1981;51(1):141\u201355.","journal-title":"J Neurol Sci"},{"issue":"1","key":"2850_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0022-510X(84)90053-4","volume":"64","author":"Z Argov","year":"1984","unstructured":"Argov Z, Yarom R. \u201cRimmed vacuole myopathy\u201d sparing the quadriceps. A unique disorder in Iranian Jews. J Neurol Sci. 1984;64(1):33\u201343.","journal-title":"J Neurol Sci"},{"issue":"11","key":"2850_CR3","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1212\/01.wnl.0000041631.28557.c6","volume":"59","author":"I Nishino","year":"2002","unstructured":"Nishino I, Noguchi S, Murayama K, Driss A, Sugie K, Oya Y, Nagata T, Chida K, Takahashi T, Takusa Y, et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology. 2002;59(11):1689\u201393. https:\/\/doi.org\/10.1212\/01.wnl.0000041631.28557.c6.","journal-title":"Neurology"},{"issue":"4","key":"2850_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/jnnp-2013-307051","volume":"86","author":"I Nishino","year":"2015","unstructured":"Nishino I, Carrillo-Carrasco N, Argov Z. GNE myopathy: current update and future therapy. J Neurol Neurosur Ps. 2015;86(4):385\u201392. https:\/\/doi.org\/10.1136\/jnnp-2013-307051.","journal-title":"J Neurol Neurosur Ps"},{"issue":"11","key":"2850_CR5","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1038\/s41436-021-01259-x","volume":"23","author":"N Carrillo","year":"2021","unstructured":"Carrillo N, Malicdan MC, Leoyklang P, Shrader JA, Joe G, Slota C, Perreault J, Heiss JD, Class B, Liu CY, et al. Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study. Genet Med. 2021;23(11):2067\u201375. https:\/\/doi.org\/10.1038\/s41436-021-01259-x.","journal-title":"Genet Med"},{"issue":"1","key":"2850_CR6","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1212\/NXG.0000000000000308","volume":"5","author":"O Pogoryelova","year":"2019","unstructured":"Pogoryelova O, Wilson IJ, Mansbach H, Argov Z, Nishino I, Lochmuller H. GNE genotype explains 20% of phenotypic variability in GNE myopathy. Neurol Genet. 2019;5(1):e308. https:\/\/doi.org\/10.1212\/NXG.0000000000000308.","journal-title":"Neurol Genet"},{"issue":"8","key":"2850_CR7","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/humu.22583","volume":"35","author":"FV Celeste","year":"2014","unstructured":"Celeste FV, Vilboux T, Ciccone C, de Dios JK, Malicdan MC, Leoyklang P, McKew JC, Gahl WA, Carrillo-Carrasco N, Huizing M. Mutation update for GNE gene variants associated with GNE myopathy. Hum Mutat. 2014;35(8):915\u201326. https:\/\/doi.org\/10.1002\/humu.22583.","journal-title":"Hum Mutat"},{"key":"2850_CR8","doi-asserted-by":"publisher","first-page":"1002310","DOI":"10.3389\/fneur.2022.1002310","volume":"13","author":"J Mullen","year":"2022","unstructured":"Mullen J, Alrasheed K, Mozaffar T. GNE myopathy: history, etiology, and treatment trials. Front Neurol. 2022;13:1002310. https:\/\/doi.org\/10.3389\/fneur.2022.1002310.","journal-title":"Front Neurol"},{"issue":"5","key":"2850_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.nmd.2014.02.008","volume":"24","author":"M Mori-Yoshimura","year":"2014","unstructured":"Mori-Yoshimura M, Oya Y, Yajima H, Yonemoto N, Kobayashi Y, Hayashi YK, Noguchi S, Nishino I, Murata M. GNE myopathy: a prospective natural history study of disease progression. Neuromuscul Disord. 2014;24(5):380\u20136. https:\/\/doi.org\/10.1016\/j.nmd.2014.02.008.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2850_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ng718","volume":"29","author":"I Eisenberg","year":"2001","unstructured":"Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, Barash M, Shemesh M, Sadeh M, Grabov-Nardini G, et al. The UDP-N-acetylglucosamine 2-epimerase\/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet. 2001;29(1):83\u20137. https:\/\/doi.org\/10.1038\/ng718.","journal-title":"Nat Genet"},{"issue":"1","key":"2850_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1212\/wnl.61.1.145","volume":"61","author":"S Hinderlich","year":"2003","unstructured":"Hinderlich S, Salama I, Eisenberg I, Mitrani-Rosenbaum S. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology. 2003;61(1):145. https:\/\/doi.org\/10.1212\/wnl.61.1.145.","journal-title":"Neurology"},{"issue":"12","key":"2850_CR12","doi-asserted-by":"publisher","first-page":"11402","DOI":"10.1074\/jbc.M313171200","volume":"279","author":"S Noguchi","year":"2004","unstructured":"Noguchi S, Keira Y, Murayama K, Ogawa M, Fujita M, Kawahara G, Oya Y, Imazawa M, Goto Y, Hayashi YK, et al. Reduction of UDP-N-acetylglucosamine 2-epimerase\/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles. J Biol Chem. 2004;279(12):11402\u20137. https:\/\/doi.org\/10.1074\/jbc.M313171200.","journal-title":"J Biol Chem"},{"issue":"22","key":"2850_CR13","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1093\/hmg\/ddm220","volume":"16","author":"MC Malicdan","year":"2007","unstructured":"Malicdan MC, Noguchi S, Nonaka I, Hayashi YK, Nishino I. A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. Hum Mol Genet. 2007;16(22):2669\u201382. https:\/\/doi.org\/10.1093\/hmg\/ddm220.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"2850_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nm.1956","volume":"15","author":"MC Malicdan","year":"2009","unstructured":"Malicdan MC, Noguchi S, Hayashi YK, Nonaka I, Nishino I. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat Med. 2009;15(6):690\u20135. https:\/\/doi.org\/10.1038\/nm.1956.","journal-title":"Nat Med"},{"issue":"7","key":"2850_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s41231-018-0025-0","volume":"3","author":"N Suzuki","year":"2018","unstructured":"Suzuki N, Kato M, Warita H, Izumi R, Tateyama M, Kuroda H, Asada R, Suzuki A, Yamaguchi T, Nishino I, Aoki M. Phase I clinical trial results of aceneuramic acid for GNE myopathy in Japan. Transl Med Commun. 2018;3(7):7.","journal-title":"Transl Med Commun"},{"issue":"1","key":"2850_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JND-159900","volume":"3","author":"Z Argov","year":"2016","unstructured":"Argov Z, Caraco Y, Lau H, Pestronk A, Shieh PB, Skrinar A, Koutsoukos T, Ahmed R, Martinisi J, Kakkis E. Aceneuramic acid extended release administration maintains upper limb muscle strength in a 48-week study of subjects with GNE myopathy: results from a phase 2, randomized. Controll Study J Neuromuscul Dis. 2016;3(1):49\u201366. https:\/\/doi.org\/10.3233\/JND-159900.","journal-title":"Controll Study J Neuromuscul Dis"},{"key":"2850_CR17","doi-asserted-by":"publisher","DOI":"10.3233\/JND-230029","author":"N Suzuki","year":"2023","unstructured":"Suzuki N, Mori-Yoshimura M, Katsuno M, Takahashi M, Yamashita S, Oya Y, Hashizume A, Yamada S, et al. Phase II\/III study of aceneuramic acid administration for GNE myopathy in Japan. J Neuromuscul Dis. 2023. https:\/\/doi.org\/10.3233\/JND-230029.","journal-title":"J Neuromuscul Dis"},{"issue":"18","key":"2850_CR18","doi-asserted-by":"publisher","first-page":"e2109","DOI":"10.1212\/WNL.0000000000006932","volume":"92","author":"H Lochmuller","year":"2019","unstructured":"Lochmuller H, Behin A, Caraco Y, Lau H, Mirabella M, Tournev I, Tarnopolsky M, Pogoryelova O, Woods C, Lai A, et al. A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy. Neurology. 2019;92(18):e2109\u201317. https:\/\/doi.org\/10.1212\/WNL.0000000000006932.","journal-title":"Neurology"},{"key":"2850_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13023-014-0150-4","volume":"9","author":"M Mori-Yoshimura","year":"2014","unstructured":"Mori-Yoshimura M, Hayashi YK, Yonemoto N, Nakamura H, Murata M, Takeda S, Nishino I, Kimura E. Nationwide patient registry for GNE myopathy in Japan. Orphanet J Rare Dis. 2014;9:150. https:\/\/doi.org\/10.1186\/s13023-014-0150-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2850_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3233\/JND-200565","volume":"8","author":"H Lochmuller","year":"2021","unstructured":"Lochmuller H, Behin A, Tournev I, Tarnopolsky M, Horvath R, Pogoryelova O, Shah J, Koutsoukos T, Skrinar A, Kakkis E, et al. Results from a 3-year non-interventional, observational disease monitoring program in adults with GNE myopathy. J Neuromuscul Dis. 2021;8(2):225\u201334. https:\/\/doi.org\/10.3233\/JND-200565.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"2850_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.nmd.2017.11.001","volume":"28","author":"O Pogoryelova","year":"2018","unstructured":"Pogoryelova O, Cammish P, Mansbach H, Argov Z, Nishino I, Skrinar A, Chan Y, Nafissi S, Shamshiri H, Kakkis E, et al. Phenotypic stratification and genotype\u2013phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: first report from the GNE myopathy disease monitoring program, registry portion. Neuromuscul Disord. 2018;28(2):158\u201368. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.001.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"2850_CR22","doi-asserted-by":"publisher","first-page":"e000362","DOI":"10.1136\/bmjno-2022-000362","volume":"4","author":"M Mori-Yoshimura","year":"2022","unstructured":"Mori-Yoshimura M, Yajima H, Oya Y, Mizuno K, Noguchi S, Nishino I, Takahashi Y. Long-term evaluation parameters in GNE myopathy: a 5-year observational follow-up natural history study. BMJ Neurol Open. 2022;4(2):e000362. https:\/\/doi.org\/10.1136\/bmjno-2022-000362.","journal-title":"BMJ Neurol Open"},{"issue":"5","key":"2850_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/WCO.0000000000001090","volume":"35","author":"W Yoshioka","year":"2022","unstructured":"Yoshioka W, Nishino I, Noguchi S. Recent advances in establishing a cure for GNE myopathy. Curr Opin Neurol. 2022;35(5):629\u201336. https:\/\/doi.org\/10.1097\/WCO.0000000000001090.","journal-title":"Curr Opin Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02850-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T01:12:16Z","timestamp":1700269936000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02850-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02850-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2874819\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"3 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Tohoku University Hospital. All patients gave informed, written consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All study subjects provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}